

Alzheimer Disease

New Drugs, Markets & Companies

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

September 2017

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is CEO and consultant at Jain PharmaBiotech. Prof. Jain's 470 publications including 28 books (5 as editor + 23 as author) and 50 special reports, which cover important areas in biotechnology, cell/gene therapies and biopharmaceuticals. Recent books relevant to the nervous system include "Handbook of Neuroprotection" (Springer, 2011) and "Applications of Biotechnology in Neurology" (Springer 2013). In addition to the above, he has edited "Applied Neurogenomics" (Springer 2015).

**September 2017 (first edition in 2003)
Copyright © 2017 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Clinical Features, Epidemiology and Pathology	19
Introduction	19
Historical aspects	19
Clinical features of Alzheimer disease.....	20
Seven stages of Alzheimer disease.....	22
AD as a terminal illness	24
Detection of AD in the preclinical phase	24
Differentiation of AD from other dementias	24
Differentiation of AD from non-dementing disorders	26
Cerebral insufficiency and AD	26
Memory deficits and preclinical AD	26
Sleep disorders and AD.....	27
<i>Circadian rhythms and sleep in AD</i>	<i>27</i>
Mild cognitive impairment	28
Evolution of diagnostic criteria of AD	29
Revised criteria for the clinical diagnosis of AD	31
Epidemiology	32
Epidemiology of aging	32
Epidemiology of dementia	34
Epidemiology of AD.....	35
<i>Prevalence of AD according to age</i>	<i>35</i>
<i>Mortality in AD.....</i>	<i>35</i>
Pathophysiology of AD.....	35
Cerebral atrophy and neuronal loss	35
Neuritic plaques and neurofibrillary tangles	36
See-through 3D imaging of the AD brain.....	36
Sp proteins as markers of neuronal death in AD.....	37
Role of tau in the pathogenesis of AD	37
RNA-binding proteins and AD	38
Amyloid precursor protein	39
<i>Relation of APP mutations to CNS disorders.....</i>	<i>39</i>
<i>Relation of APP to Aβ deposits and pathogenesis of AD</i>	<i>40</i>
<i>APP intracellular domain</i>	<i>41</i>
<i>Role of neprilysin in Aβ degradation</i>	<i>41</i>
<i>Role of secretases in amyloid cascade</i>	<i>41</i>
<i>Role of exosomal proteins</i>	<i>43</i>
<i>Role of nicastrin.....</i>	<i>43</i>
Neurotoxicity of A β deposits	43
<i>Dysfunction of TGF-β signaling accelerates Aβ deposition</i>	<i>44</i>
<i>Interaction of Aβ with neuron-specific Na⁺/K⁺-ATPase α3 subunit</i>	<i>45</i>
<i>Relation of Aβ deposits to synaptic activity.....</i>	<i>45</i>
<i>Role of TMP21 in presenilin complexes and Aβ formation</i>	<i>45</i>
<i>Role of Aβ dimers in the pathogenesis of AD.....</i>	<i>46</i>
<i>Aβ-mediated synaptic and cognitive deficits</i>	<i>46</i>
<i>Role of dsDNA breaks in neurodegeneration due to Aβ.....</i>	<i>46</i>
<i>Structure-neurotoxicity relationships of Aβ oligomers.....</i>	<i>47</i>
<i>Sequence of events in neurotoxicity of Aβ.....</i>	<i>48</i>
A β production and clearance	49
Impairment of mitochondrial energy metabolism	50
<i>Aβ-binding alcohol dehydrogenase links AD to mitochondrial toxicity</i>	<i>50</i>
Neural thread protein	50
Loss of synaptic proteins.....	50
<i>AD and Down syndrome.....</i>	<i>51</i>
<i>Overlapping pathologies of AD and Parkinson disease.....</i>	<i>51</i>
<i>AD and age-related macular degeneration.....</i>	<i>52</i>
<i>Myelin hypothesis of AD.....</i>	<i>52</i>
<i>Blood-brain barrier in AD</i>	<i>52</i>
<i>Blood vessel damage in AD</i>	<i>53</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>54</i>
Factors in pathogenesis of AD.....	54
<i>Astrocytes and AD.....</i>	<i>54</i>
<i>Axonal transport failure in AD.....</i>	<i>55</i>
<i>Cell-cycle hypothesis</i>	<i>55</i>
<i>Chronic heart failure link with AD.....</i>	<i>55</i>
<i>Creatine and AD</i>	<i>56</i>
<i>Disturbances in brain metabolism in early AD.....</i>	<i>56</i>

<i>Disturbances of interaction of nervous system proteins</i>	56
<i>Disturbance of lipid metabolism in the brain</i>	57
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD</i>	57
<i>Gonadotrophins and AD</i>	57
<i>Glutamate transport dysfunction in AD</i>	58
<i>Herpes simplex virus type 1 and AD</i>	59
<i>Innate immune system and AD</i>	59
<i>Insulin, diabetes and AD</i>	59
<i>Mechanisms underlying cognitive deficits in AD</i>	61
<i>Monoamine oxidase and AD</i>	62
<i>Neuroinflammation and AD</i>	62
<i>Neurotransmitter deficits</i>	64
<i>Role of dopamine in AD</i>	64
<i>Neurotrophic factors</i>	64
<i>NF-κB signaling and the pathogenesis of neurodegeneration</i>	65
<i>Nitric oxide and AD</i>	65
<i>Nogo receptor pathway</i>	68
<i>Oxidative stress and AD</i>	68
<i>Prostaglandins and AD</i>	70
<i>Quinolinic acid and AD</i>	70
<i>Retromer deficiency</i>	70
<i>Serotonin and AD</i>	71
Spread of neurodegeneration.....	71
<i>Synaptic failure in AD</i>	71
<i>Transmission of AD</i>	72
<i>Ubiquitin-proteasome system in pathogenesis of AD</i>	73
Risk factors in the etiology of AD.....	74
<i>Aging and developmental abnormalities of the cholinergic system</i>	74
<i>Cholesterol, dietary lipids, and Aβ</i>	75
<i>Exposure to magnetic fields</i>	76
<i>Family history of AD</i>	76
<i>Homocysteine and AD</i>	76
<i>Hypertension and AD</i>	77
<i>Level of education/type of job and risk of AD</i>	77
<i>Metals and AD</i>	78
<i>Obesity</i>	79
<i>Proneness to psychological distress and risk of AD</i>	80
<i>Reduced muscle strength</i>	80
<i>Sleep deprivation</i>	80
<i>Traumatic brain injury and AD</i>	81
<i>Vascular risk factors for AD</i>	82
<i>Vitamin B12 and folate</i>	83
AD versus non-dementing changes in the aging brain.....	84
AD and cognitive impairment with aging.....	84
Pathomechanism of memory impairment and AD.....	84
Concluding remarks on pathophysiology of AD.....	85
Genetics of AD	87
Familial AD.....	87
<i>Molecular genetics of familial AD</i>	87
<i>Presenilins and calcium channel pathogenesis of familial AD</i>	88
<i>Presenilin-1 mutations and familial AD</i>	88
Late onset AD.....	89
Genomics of AD	89
Introduction to genomics.....	89
Genes associated with Alzheimer disease.....	90
<i>AlzGene database</i>	91
<i>ApoE gene</i>	91
<i>ApoE genotype and nitric oxide</i>	93
<i>ApoE genotype modulates AD phenotype</i>	93
<i>APOE genotype and age-related myelin breakdown</i>	94
<i>ApoE receptor interaction with NMDA receptor</i>	94
<i>ApoE and ApoER2</i>	94
<i>ApoE receptor LR11 as regulator of Aβ</i>	95
<i>Arctic mutation</i>	95
<i>BCH E gene</i>	95
<i>CALHM1 polymorphism and AD</i>	95
<i>CLU, CRI and PICALM</i>	96
<i>CYP46 and risk for AD</i>	96
<i>DAPK1 gene variants and AD</i>	97
Genetic variants associated with early-onset AD.....	97
Genetic variants associated with late-onset AD.....	97

<i>ApoE</i> polymorphisms associated with LOAD.....	97
Copy number variation (CNV) in LOAD.....	98
<i>LRRTM3</i> as a candidate gene for AD.....	98
<i>MTHFD1L</i> gene variant associated with AD.....	98
Mutation in <i>APP</i> gene with protective effect against AD.....	99
<i>OGG1</i> mutations associated with AD.....	99
<i>SORL1</i> gene in AD.....	99
<i>TOMM40</i> gene and risk of AD.....	99
<i>TREM2</i> variants in AD.....	100
International Genomics of Alzheimer's Project.....	100
Sequencing in Alzheimer disease.....	101
Molecular neuropathology.....	103
Role of microRNAs in AD.....	103
DNA methylation in AD.....	104
AD as a polygenic disorder.....	104
Proteomics of AD.....	105
Introduction.....	105
Application of proteomic technologies to study AD.....	105
Protein misfolding in AD.....	107
Common denominators of AD and prion diseases.....	108
2. Diagnostic Procedures for Alzheimer Disease.....	109
Importance of the diagnosis of Alzheimer disease.....	109
Methods of diagnosis of AD.....	109
Self-administered olfactory test.....	110
Neuropsychological testing.....	110
Assessment and evaluation.....	111
7-minute screen.....	111
15-point risk index.....	112
Activities of Daily Living.....	112
Alzheimer Disease Cooperative Study.....	112
CDR-SOB score.....	112
Clinician's Interview-Based Impression of Change.....	113
DETECT™ System.....	113
Measurement of aggregation in anterior segment of the eye.....	113
Resource Utilization in Dementia Battery.....	113
SymptomGuide™.....	113
Electrophysiology.....	114
Quantitative EEG for investigation of early AD.....	114
EEG-based bispectral index.....	114
Event-related potentials.....	114
Correlation of electrical activity of the brain with cognition.....	115
Early detection of cataract associated with AD.....	115
Retinal imaging to detect A β deposits.....	115
Laboratory methods for diagnosis of AD.....	116
Monitoring of synthesis and clearance rates of A β in the CSF.....	117
Molecular diagnostics for AD.....	117
Genetic tests for AD.....	118
<i>ApoE</i> genotyping.....	119
Gene expression patterns in AD.....	119
Monoclonal antibody-based in vitro diagnosis of AD from brain tissues.....	119
Multi-tissue RNA signature of aging as diagnostic for AD.....	119
Biomarkers of AD.....	120
The ideal biomarker for AD.....	122
CSF biomarkers of AD.....	122
CSF sulfatide as a biomarker for AD.....	122
Glycerophosphocholine as CSF biomarker in AD.....	123
Protein biomarkers of AD in CSF.....	123
Tau proteins in CSF.....	125
Tests for the detection of A β in CSF.....	125
Tests combining CSF tau and A β	126
Concluding remarks about CSF biomarkers of AD.....	126
Urine tests for AD.....	127
Blood tests for AD.....	127
Blood A β levels.....	127
Blood test for AD based on heme oxygenase-1.....	128
Blood test for AD based on RNA hybridization.....	128
GSK-3 elevation in white blood cells.....	128
Lipid biomarkers for preclinical detection of AD.....	129
Lymphocyte Proliferation Test.....	129
Metabolomic biomarker profiling.....	129

<i>MGAT3 as biomarker for prognosis of AD</i>	130
<i>MicroRNA-based test for AD</i>	130
<i>Protein kinase C in red blood cells</i>	130
<i>Sphingolipids</i>	130
<i>Tests based on protein biomarkers in blood</i>	131
A skin test for early detection of AD	131
Saliva-based tests for AD	132
<i>Saliva Aβ42 level as a biomarker of AD</i>	132
Nanotechnology to measure A β -derived diffusible ligands	132
Simultaneous measurement of several biomarkers for AD	133
Nutritional biomarkers in plasma of AD patients	133
Plasma biomarkers of drug response in AD	134
A serum protein-based algorithm for the detection of AD	134
Concluding remarks about biomarkers for AD	134
Imaging in AD	135
Computed tomography	135
Magnetic resonance imaging	135
<i>Arterial spin labeling with MRI</i>	136
<i>Magnetic resonance microscopy</i>	136
<i>Magnetic resonance spectroscopy</i>	136
Single photon emission computed tomography and modifications	137
Positron emission tomography	138
In vivo imaging of A β deposits by PET	139
<i>Pittsburgh compound B and PET</i>	140
<i>Florbetapir-PET</i>	141
<i>Florbetaben-PET</i>	142
<i>Flutemetamol-PET</i>	142
<i>Future prospects of the PET imaging in AD</i>	142
In vivo detection of A β plaques by MRI	143
Imaging agents for A β and neurofibrillary tangles	143
Targeting of a chemokine receptor as biomarker for brain imaging	144
Radioiodinated cloquinol as a biomarker for A β	144
Imaging neuroinflammation in AD	145
Preclinical diagnosis of AD	145
<i>Correlation of imaging with CSF biomarkers for early detection of AD</i>	146
Meta-analysis of literature on imaging in AD	146
Alzheimer Disease Neuroimaging Initiative	146
Computer aided diagnosis systems for AD based on imaging data	147
Concluding remarks on imaging for diagnosis of AD	148
Diagnosis of MCI and prediction of AD	148
Diagnosis of MCI	148
<i>Computer-Administered Neuropsychological screen for MCI</i>	148
<i>Infrared eye-tracking technology to detect MCI</i>	149
<i>MRI for detection of MCI</i>	149
<i>PET for detection of MCI</i>	149
<i>Role of APOE genotype in early MCI</i>	150
Presymptomatic detection of AD	150
<i>Biomarker changes in autosomal dominantly inherited AD</i>	151
<i>Blood test for preclinical diagnosis of AD</i>	151
<i>Gait analysis during cognitive tasks</i>	151
PredictAD project	152
Prediction of AD in patients with MCI	152
<i>Biochemical biomarkers in CSF for prediction of AD</i>	152
<i>Clinical and biochemical biomarkers for profiling prodromal AD</i>	153
<i>Combination of MMSE and a memory test for prediction of AD</i>	153
<i>Plasma protein biomarkers of conversion of MCI to AD</i>	153
<i>Structural MRI biomarkers for prediction of AD</i>	153
<i>Magnetoencephalography for detection of MCI and AD</i>	154
<i>MRI-based index to measure the severity of AD in MCI</i>	154
<i>Concluding remarks about prediction of AD in MCI</i>	154
Criteria for diagnosis of AD	155
Role of biomarkers in diagnosis of AD dementia	156
Ethical aspects of diagnostics for AD	157
Genetic testing for AD	157
Ethical issues of brain imaging in AD	158
Monitoring of treatment of AD	158
<i>Monitoring treatment of mixed AD and vascular dementia</i>	158
Companies involved in diagnosis of AD	159
3. Management of Alzheimer Disease	161
Introduction	161

Cholinergic approaches.....	161
Mechanism of action of cholinesterase inhibitors	162
Choline and lecithin.....	163
Donepezil.....	164
Rivastigmine	165
Galantamine.....	166
Duration of treatment with ChE inhibitors	167
Comparative studies of ChE inhibitors	167
Donepezil versus rivastigmine	168
Donepezil versus galantamine	168
Combination of cholinesterase inhibitors and a cholinergic precursor	168
An assessment and future prospects of anticholinergic therapies.....	169
Neuroprotection in Alzheimer's disease.....	170
Memantine.....	170
<i>Pharmacology of memantine</i>	<i>170</i>
<i>Clinical trials of memantine</i>	<i>171</i>
<i>Combination of memantine with ChE inhibitors</i>	<i>173</i>
Monoamine oxidase inhibitors.....	174
<i>Selegiline.....</i>	<i>174</i>
Synaptoprotection in AD	174
Drugs for noncognitive symptoms in AD	175
Antidepressants.....	175
Antipsychotics	175
ChE inhibitors for behavioral and psychological disorders in AD.....	176
Concluding remarks and other drugs for agitation in AD.....	176
Sensory stimulation	177
Non-pharmacological treatments of AD	177
Cerebrospinal fluid shunting	177
Deep brain stimulation	178
Exposure of the brain to electromagnetic fields for treatment of AD	179
<i>Application of electrical fields for improvement of cerebral function</i>	<i>179</i>
<i>High-frequency electromagnetic field treatment of AD</i>	<i>179</i>
<i>Transcranial magnetic stimulation</i>	<i>180</i>
Mental training for management of memory loss in AD	180
Microchip-based hippocampal prosthesis for AD	180
Omental transposition	181
Photo-induced inhibition of A β accumulation in AD	181
Scanning ultrasound for removal of A β	181
Vagal nerve stimulation	182
Nutritional therapies for AD.....	182
Axona.....	182
Cocktail of dietary supplements for AD	182
Docosahexaenoic acid.....	183
Magnesium	184
Nicotinamide for the treatment of AD	185
Omega-3 fatty acids.....	185
Preventing decline of mental function with aging and dementia.....	186
Prevention of Alzheimer disease.....	187
<i>Mental training</i>	<i>188</i>
<i>Physical exercise.....</i>	<i>188</i>
<i>Higher level of conscientiousness and decreased risk of AD</i>	<i>189</i>
Nutritional factors in prevention of AD and MCI.....	189
<i>Black and green teas</i>	<i>190</i>
<i>Caffeine.....</i>	<i>190</i>
<i>Caloric restriction.....</i>	<i>191</i>
<i>Cinnamon</i>	<i>191</i>
<i>Cocoa flavonol consumption</i>	<i>191</i>
<i>Grapes and red wine</i>	<i>191</i>
<i>Vitamin D and docosahexaenoic acid</i>	<i>193</i>
Drugs to prevent Alzheimer disease	193
Preimplantation genetic diagnosis of inherited Alzheimer disease	193
Presymptomatic detection of AD	193
Management of mild cognitive impairment.....	194
Slowing the progression of MCI to AD.....	194
Management of Down syndrome.....	195
Guidelines for use of anti-dementia drugs in clinical practice.....	196
Donepezil and/or memantine.....	196
General care of the Alzheimer disease patients	197
Strategies for the management of Alzheimer disease.....	197
4. Research in Alzheimer Disease	199

Introduction	199
Animal models of Alzheimer disease.....	199
Lesional models	199
<i>Cerebroventricular injection of Aβ in rats</i>	<i>199</i>
<i>Lentiviral vector-based models of amyloid pathology</i>	<i>200</i>
<i>AAV-mediated gene transfer to increase hippocampal Aβ</i>	<i>200</i>
Transgenic mouse models	200
<i>Quantitative assessment of amyloid load in transgenic models.....</i>	<i>201</i>
<i>In vivo magnetic resonance microimaging in transgenic models of AD</i>	<i>202</i>
<i>Transgenic model of AD with suppression of Aβ production.....</i>	<i>202</i>
<i>Transgenic AD11 anti-NGF mice.....</i>	<i>202</i>
<i>Genetically altered mice with deficiency of vesicular ACh transporter.....</i>	<i>203</i>
<i>Limitations of mouse models of Alzheimer disease</i>	<i>203</i>
<i>Improved mouse models of AD expressing human genes</i>	<i>204</i>
Cholesterol-fed rabbits as models for AD.....	204
Canine dementia as model for AD	204
Zebrafish model for AD	205
Transgenic invertebrate models of Alzheimer disease	206
<i>Drosophila model of AD</i>	<i>206</i>
<i>Caenorhabditis elegans Alzheimer disease model</i>	<i>206</i>
Correlation of studies in animal models and human clinical trials.....	207
Cell systems for AD research	208
In vitro neuronal cell Lines	208
Single-gene expression system for use in cell culture	208
Stem cells for testing efficacy of AD drugs	208
Transgenic cells	209
In silico models	209
Estimation of progression rates of Alzheimer disease.....	210
Clinical trial methods in Alzheimer disease.....	210
Molecular imaging as a guide to drug development	211
Use of MRI and PET in clinical trials	211
Cognitive-function assessment in clinical trials.....	212
Clinical trials in mild cognitive impairment.....	212
Research in AD as a basis for future therapies.....	213
Use of microarrays for studying pathogenesis of AD	213
Computational brain mapping in AD	213
Study of neurogenesis in AD	213
Study of 3D structure of A β	213
Solid-state NMR to study precursors of A β	214
Research in Alzheimer disease at academic centers	214
Role of NIH in AD research.....	214
NIH Clinical Trials Database for AD.....	214
Alzheimer Research Consortium.....	214
The National Institute on Aging and AD research	215
5. Drug Discovery & Development for Alzheimer Disease	217
Introduction	217
Categories of drugs in development for AD.....	217
Memory-enhancing drugs	219
Enhancing memory by drugs that block eIF2 α phosphorylation	219
Drugs based on cholinergic approaches.....	219
AP2238.....	220
Butyrylcholinesterase inhibitors	220
Donepezil-tacrine hybrids.....	220
Drugs modulating gamma-aminobutyric acid receptors.....	221
Ganstigmina.....	221
Methanesulfonyl fluoride	221
Muscarinic receptor modulators	222
<i>Muscarinic M1 agonists</i>	<i>222</i>
<i>Muscarinic M2 antagonists.....</i>	<i>223</i>
Nicotine and nicotinic receptor modulators	223
<i>Nicotine</i>	<i>223</i>
<i>Nicotinic receptor modulators</i>	<i>224</i>
<i>GTS21</i>	<i>226</i>
<i>Ispronicline</i>	<i>227</i>
<i>JWB1-84-1.....</i>	<i>227</i>
Neuropeptide/neurotransmitters	227
Somatostatin release enhancers	227
Glutamate receptor modulators	228
Physiology and pharmacology of glutamate receptors.....	228
NMDA receptor ion channel complex.....	228

Metabotropic glutamate receptors	229
Glutamate receptor modulators as potential therapeutics for AD	230
<i>N20C</i>	231
<i>AMPA modulators</i>	231
Glutamate release inhibitors.....	232
<i>INI-0602</i>	232
Drugs affecting multiple neurotransmitters	232
Ensaculin	232
RS-1259	232
Lecozotan	232
Vaccines for AD.....	233
Active immunization with A β	233
<i>AN-1792 vaccine</i>	233
<i>Complications in clinical trials with AN-1792</i>	234
<i>Effects of Aβ vaccine on the brain</i>	234
Strategies to avoid undesirable effect of A β vaccination	235
Passive immunization in AD.....	236
<i>Passive immunization with MAbs</i>	236
<i>Clinical trials of MAbs in AD</i>	237
<i>Delivery of the passive antibody directly to the brain</i>	238
<i>Systemic injection of MAbs to treat AD</i>	239
Combination of A β immunotherapy and CD40-CD40L blockade	239
Shaping the immune responses elicited against A β	239
Delivery of AD vaccines	240
<i>Gene vaccination</i>	240
<i>Modified Aβ nasal vaccine</i>	241
<i>Transdermal Aβ vaccination</i>	241
Other vaccines for AD.....	241
<i>Nasal vaccination with Proteosome™ adjuvant</i>	242
<i>T cell vaccination with glatiramer acetate adjuvant</i>	242
Early start of immunotherapy for clearing A β plaques	242
Reversal of cholinergic dysfunction by anti-A β antibody	242
Immune modulation via Toll-like receptors to reduce A β	243
Mechanisms by which A β antibodies reduce amyloid accumulation in the brain	243
Perspectives on vaccines for AD.....	244
Companies involved in AD vaccines	246
Inhibition of amyloid precursor protein aggregation	246
Secretase modulators.....	246
<i>Neuroprotection by α-secretase cleaved APP</i>	247
<i>Inhibitors of β-secretase</i>	248
<i>Inhibitors of γ-secretase</i>	249
Amyloid-derived diffusible ligands	251
GABA receptor modulation by etazolate and APP processing	251
Depletion of serum amyloid P	251
Drugs that inhibit the formation of Aβ	251
22R-hydroxycholesterol	252
Acylaminopyrazole	252
Cadmium telluride nanoparticles prevent A β fibril formation	252
Cannabinoids.....	253
Chelation therapy for AD.....	253
<i>Clioquinol and PBT2</i>	254
<i>Copper chelation by FKBP52</i>	255
<i>Zinc chelation from amyloid plaques</i>	256
<i>Next generation multifunctional chelating agents for AD</i>	256
Heparin and its derivatives.....	257
<i>A reassessment of the role of heparin in AD</i>	257
<i>Enoxaparin</i>	257
<i>Heparan sulfate</i>	257
Imatinib mesylate	258
Laminin	258
Masitinib	258
NSAIDs.....	259
<i>Flurbiprofen analogs with Aβ42-lowering action</i>	259
<i>Nitric oxide-donating NSAIDs</i>	260
<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i>	261
Paclitaxel	261
Phenserine.....	261
<i>Tolserine</i>	262
Platinum-based inhibitors of A β	262
Retro-inverso peptide inhibitor	262
Scyllo-cyclohexanehexol	263

Selective serotonin reuptake inhibitor	263
Small molecule drug discovery for inhibiting A β aggregation.....	263
Trojan-horse approach to prevent build-up of A β aggregates.....	264
Ubiquitin C-terminal hydrolase L1	264
Drugs to prevent the formation of NFTs.....	264
Tau suppression.....	265
Anthraquinones	265
Anti-tau antibodies.....	266
Tau aggregation inhibitor rember™	266
LMTX®	266
Microtubule stabilizers	266
ApoE4 as a therapeutic target in AD	266
Strategies to prevent deposits and enhance clearance of Aβ	267
4,5-dianilinophthalimide for disruption of A β ₁₋₄₂ fibrils.....	268
ABCA1 overexpression to lower amyloid deposits	268
ANAVEX 2-73	269
Beta-sheet breakers.....	269
Bexarotene	269
Blocking ApoE/A β interaction to reduce A β plaques	270
CD33 inhibitors.....	270
Clearance of A β across the blood-brain barrier.....	270
Enhanced PKC ϵ activity promotes clearance of A β	271
Galantamine-induced A β clearance.....	271
Hemopheresis	271
Inhibitors of A β dehydrogenase	272
Intravenous immune globulin	272
Monoclonal antibodies for removal of A β	273
<i>Crenezumab</i>	273
<i>Gantenerumab</i>	273
<i>Solanezumab</i>	274
Nanotechnology for removal of A β deposits	274
Role of matrix metalloproteinases in clearance of A β	274
SAN-61 for cleavage of fibril and soluble amyloid.....	275
Serum amyloid P component depletion	275
Small molecule DAPH for clearance of amyloid.....	275
Companies developing Aβ-directed therapeutics for AD	276
Nootropics	277
Acetyl-L-carnitine.....	277
Cerebrolysin.....	278
Ergot derivatives.....	278
<i>Lisuride</i>	278
<i>Dihydroergocryptine</i>	279
Neuroprotective effect drugs not primarily developed for AD	279
Antiinflammatory and antimicrobial drugs	280
<i>Dapsone</i>	280
<i>Antimicrobial drugs against C. pneumoniae</i>	280
<i>PPAR-gamma agonists</i>	280
Antidiabetic drugs	281
<i>Insulin</i>	281
<i>Metformin</i>	281
<i>Rosiglitazone</i>	282
<i>Pioglitazone</i>	282
Antihypertensive drugs	283
<i>Angiotensin-converting enzyme inhibitors</i>	283
<i>Angiotensin receptor blockers</i>	283
Bexarotene	283
Dimebon.....	283
Drugs acting on estrogen receptors.....	284
<i>Estrogen</i>	285
<i>Raloxifene</i>	285
Inhibitors of neuroinflammation	286
<i>Ceramide</i>	286
<i>CSP-1103</i>	286
<i>Cyclophosphamide</i>	286
<i>Etanercept</i>	287
<i>Fingolimod</i>	287
<i>Interferon beta-1a</i>	287
<i>MW01-5-188WH</i>	288
Neurosteroids.....	288
<i>Pregnenolone sulfate</i>	288
<i>Dehydroepiandrosterone</i>	289

Levetiracetam	289
Lithium	289
MAO-B inhibitors.....	290
<i>Ladostigil tartrate</i>	290
<i>Memoquin</i>	290
Methylene blue	291
Nilotinib	291
Nimodipine.....	291
Rapamycin.....	292
Saracatinib.....	292
Statins.....	292
Testosterone	293
Valproic acid.....	294
Future prospects of neuroprotection in AD.....	295
<i>Targeting Cdk5 pathway</i>	295
Antioxidants	295
Colostrinin	296
Curcumin	296
Dehydroascorbic acid	297
Reservatrol	297
Synthetic catalytic scavengers.....	298
Vitamins	298
Vitamin E as antioxidant	298
Vitamin B for lowering homocysteine.....	299
Folic acid	299
Aminopyridazines	299
Nanobody-based drugs for AD	300
Nitric oxide based therapeutics for AD.....	300
Nitric oxide mimetics.....	300
iNOS inhibitors for AD.....	300
Novel drugs for AD from natural resources.....	301
Berberine chloride.....	302
Centella asiatica	302
Ginko biloba.....	302
Huperzine-A	303
Hyperforin.....	304
Melissa officinalis	304
Nostocarboline derived from cyanobacteria	305
PTI-00703.....	305
Salvia.....	305
Securinega suffruticosa.....	305
Withania somnifera	306
ZT-1.....	306
Cholesterol and AD	306
ACAT inhibitors.....	307
Role of gene for cholesterol ester transfer protein	308
Cholesterol 24S-hydroxylase as a drug target for AD.....	308
Selectively increase of ApoA-I production.....	308
Neurotrophic factors.....	309
Brain derived neurotrophic factor	309
Insulin-like growth factor-1	309
Nerve growth factor	310
Neotrofin (AIT-082).....	311
Limitations of the use of NTFs for AD.....	311
Role of serotonin modulators in AD	311
Xaliproden	311
5-HT _{1A} receptor antagonists	312
5-HT ₆ antagonists	312
5-HT ₄ receptor agonists	312
<i>PRX-03140</i>	313
<i>Donecopride</i>	313
Restoration of factors deficient in the aging brain.....	314
Reversal of cognitive impairment in aging by activation of creb protein.....	314
Reversal of cognitive impairment in aging by GDF11 protein	314
Restoration of repressor element 1-silencing transcription factor.....	314
Cell therapy for AD.....	315
Stem cell transplantation for AD	315
<i>Potential benefits of grafting NSCs in AD</i>	315
<i>NSCs improve cognition in AD via BDNF</i>	316
<i>Drugs for enhancing neuronal differentiation of implanted NSCs</i>	316
Choroid plexus epithelial cells for AD	316

Implantation of encapsulated cells for delivering NGF	317
Gene therapy for AD	317
ApoE gene therapy	317
<i>APPsa gene transfer for rescuing synaptic failure in AD</i>	317
FGF2 gene transfer in AD	318
Humanin gene therapy	318
Nepriylsin gene therapy	318
NGF gene therapy	319
Targeting plasminogen activator inhibitor type-1 gene	320
Antisense approaches to AD	320
RNAi approaches to AD	321
Combined therapeutic approaches to AD	322
Drug delivery for Alzheimer disease	322
Delivery of biologicals across the BBB	323
Delivery of thyrotropin-releasing hormone analogs by molecular packaging	323
Nanoparticle-based drug delivery for Alzheimer's disease	324
Transdermal drug delivery in Alzheimer's disease	324
<i>Transdermal rivastigmine</i>	325
Intranasal delivery of therapeutics for AD	325
<i>Intranasal delivery of tacrine</i>	325
<i>Intranasal delivery of nerve growth factor to the brain</i>	325
Circadian rhythms and timing of cholinesterase inhibitor therapy	326
Clinical trials for AD	326
Drugs for AD that were discontinued in clinical trials	332
Monitoring of cognitive function during clinical trials	335
Concluding remarks on clinical trials of AD	335
Drug discovery for AD	336
Drugs acting on signaling pathways	336
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1</i>	336
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD</i>	336
<i>Inhibition of the CD40 signaling pathway</i>	337
<i>JNK pathway as a target</i>	338
<i>Mitogen-activated protein kinase pathway as target</i>	338
<i>Protein kinase C activators</i>	338
Electrophysiological detection of drug target for neuroprotection in early AD	338
Genomics-based drug discovery	339
High through screening for AD drug candidates	339
Proteomics and drug discovery for AD	340
Small molecule compounds binding to neurotrophin receptor p75NTR	340
<i>Targeting Vav in tyrosine kinase signaling pathway</i>	341
<i>LM11A-31 as p75NTR ligand</i>	341
New chemical entities for AD by combining galantamine and memantine	342
Novel rivastigmine-hydroxycinnamic acid hybrids for AD	342
Novels targets/receptors for AD drug discovery	342
<i>Activation of cerebral Rho GTPases</i>	342
<i>Activators of insulin-degrading enzyme</i>	343
<i>Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages</i>	343
<i>Calcium channel blockers</i>	343
<i>Calpain inhibitors</i>	344
<i>Casein kinase 1</i>	344
<i>Cyclin-dependent kinase-5</i>	344
<i>Drugs against arginine deprivation and immune suppression in AD</i>	345
<i>Heat shock protein 90 inhibitors</i>	345
<i>Histone deacetylase inhibitors</i>	346
<i>Inhibition of PDK1 to slow progression of both AD and prion disease</i>	346
<i>Melatonin</i>	346
<i>Neurotrophic compound J147</i>	347
<i>NF-κB inhibitors</i>	347
<i>Kinases and phosphatases as targets for AD therapeutics</i>	347
<i>Neutral sphingomyelinase inhibitors</i>	348
<i>Phosphodiesterase inhibitors</i>	348
<i>Pin 1 as a target in AD</i>	349
<i>Protein phosphatase 5 as a neuroprotective in AD</i>	349
<i>Single drugs for multiple targets in AD</i>	350
<i>Src homology-containing protein-1 inhibitors</i>	350
<i>Targeting GABAergic system</i>	350
<i>TSPO ligands</i>	350
Pharmacogenomics of Alzheimer disease	351
Biomarkers and companion diagnostics for AD	351
Personalized therapy of AD	352
Genotyping and AD therapeutics	353

Regulatory aspects of drug development for AD	353
EMA guidelines for drug development for AD	353
FDA guidelines for drug development for AD.....	354
Concluding remarks and future of AD research	355
Future for AD therapeutics	355
6. Markets & Finances of AD Care	357
Introduction	357
Pharmacoeconomics of treatment of AD	357
Quality of Life in relation to economics of AD.....	357
Costs associated with Alzheimer disease	357
Pharmacoeconomics of donepezil	358
Pharmacoeconomics studies using rivastigmine	358
Pharmacoeconomics studies using galantamine	359
Pharmacoeconomics studies using memantine.....	359
Patterns of AD care in major markets	359
Care of AD patients in the US	360
<i>Cost of care</i>	360
<i>Medicare and AD</i>	361
<i>Patterns of practice in AD care</i>	362
<i>Opinions of physicians' organizations on drugs for dementia</i>	362
Care of AD patients in the UK	363
<i>Cost of care</i>	363
<i>Patterns of practice in AD care</i>	363
<i>NICE recommendations to NHS</i>	364
Care of AD patients in Germany.....	365
Care of AD patients in France	366
Care of AD patients in Italy	366
Care of AD patients in Spain.....	366
Care of AD patients in Japan	367
Markets for AD diagnostics	367
Markets for AD therapeutics	367
Geographical markets for AD	367
Markets for currently approved drugs for AD	368
Markets for generic AD drugs	369
Statins.....	369
Future growth of AD market.....	369
Limitations of AD drug development by the biotechnology industry	370
Unmet needs in the management of AD	371
Drivers of AD markets	372
Increase of the aged populations	372
Increase in the number of approved drugs for AD	372
Limitations of the current therapies.....	373
Improvements in diagnosis	373
Increasing awareness of the disease	373
7. Companies	375
Introduction	375
Profiles of companies	375
Collaborations	525
8. References	529

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease.....	19
Table 1-2: Clinical features of Alzheimer disease	20
Table 1-3: Non-Alzheimer dementias	25
Table 1-4: A guide to evaluation for MCI due to AD.....	29
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease	30
Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease.....	31
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders.....	39
Table 1-8: Risk factors for Alzheimer's disease	74
Table 1-9: Genes linked to AD	90
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD.....	106
Table 2-1: Classification of methods of diagnosis of Alzheimer disease	109
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease	110
Table 2-3: Available molecular diagnostic tests for Alzheimer disease.....	118
Table 2-4: Biomarkers of AD in blood and CSF	120
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease	122

Table 2-6: Role of biomarkers in diagnosis of AD dementia	157
Table 2-7: Companies involved in the diagnosis/monitoring of Alzheimer disease	159
Table 3-1: Classification of treatments for Alzheimer disease	161
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease.....	162
Table 3-3: Categories of neuroprotective agents for Alzheimer disease.....	170
Table 3-4: Strategies for prevention of Alzheimer disease.....	187
Table 3-5: Guidelines for the treatment of dementia	196
Table 4-1: Transgenic mouse models of Alzheimer disease	200
Table 4-2: Correlation of studies in animal models with human clinical trials	207
Table 5-1: Classification of therapies in development for Alzheimer disease	217
Table 5-2: Drugs for AD targeting nACh receptors	226
Table 5-3: Ionotropic glutamate receptors	228
Table 5-4: Classification of mGluRs	228
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD.....	230
Table 5-6: Companies involved in developing vaccines for AD	246
Table 5-7: Preclinical studies of secretase modulators	247
Table 5-8: Secretase modulators in clinical trials	247
Table 5-9: Companies developing A β -directed therapeutics for AD.....	276
Table 5-10: Innovative neuroprotective approaches for Alzheimer disease	279
Table 5-11: Herbal therapies for AD	301
Table 5-12: Novel drug delivery methods for Alzheimer disease therapies.....	322
Table 5-13: Clinical trials in Alzheimer disease	326
Table 5-14: Discontinued, failed or inconclusive clinical trials of Alzheimer disease	332
Table 6-1: Direct and indirect costs associated with Alzheimer disease	360
Table 6-2: Prevalence of AD in major markets 2016-2026	368
Table 6-3: AD market values from 2016-2026 in major world markets	368
Table 6-4: Markets for currently approved AD drugs 2016-2026.....	369
Table 6-5: Potential markets for drugs in development 2016-2026	370
Table 6-6: Limitations of AD drug development by the biotechnology industry.....	370
Table 6-7: Factors that drive AD markets	372
Table 7-1: Major players in Alzheimer's disease therapeutics.....	375
Table 7-2: Collaborations relevant to Alzheimer disease	525

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050.	32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020	33
Figure 1-3: Prevalence of different types of dementia.....	34
Figure 1-4: A β deposits in the brain	44
Figure 1-5: Pathways for A β -induced nerve cell death	48
Figure 1-6: Mechanisms of A β clearance.....	49
Figure 1-7: Insulin signaling in Alzheimer disease and diabetes	61
Figure 1-8: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease	67
Figure 1-9: Oxidative stress and Alzheimer disease.....	69
Figure 1-10: Role of proteasome inhibition in A β generation and neurodegeneration	73
Figure 1-11: Cholesterol-related pathways to AD	75
Figure 1-12: Pathomechanism of AD	86
Figure 3-1: Metabolism of acetylcholine.....	163
Figure 3-2: Neuroprotective effective of galantamine in AD.....	167
Figure 3-3: Strategies for the management of Alzheimer disease.....	197
Figure 5-1: Activation of α 7 nicotinic acetylcholine receptors.....	225
Figure 5-2: NMDA receptor ion channel complex.....	229
Figure 5-3: Neurotoxicity due to misfolding of A β 1-42	268
Figure 5-4: Interactions of players in clinical trials of Alzheimer disease in the USA.....	326
Figure 5-5: Role of proteomics in drug discovery/development for Alzheimer disease	340
Figure 5-6: FDA industry interaction during drug development for AD	354
Figure 5-7: FDA's accelerated approval pathway in early Alzheimer disease	356
Figure 6-1: Unmet needs in the management of Alzheimer disease.....	371